Home/Filings/4/0001209191-16-092996
4//SEC Filing

Anacor Pharmaceuticals, Inc. 4

Accession 0001209191-16-092996

CIK 0001411158operating

Filed

Jan 20, 7:00 PM ET

Accepted

Jan 21, 9:00 PM ET

Size

14.9 KB

Accession

0001209191-16-092996

Insider Transaction Report

Form 4
Period: 2016-01-19
IPPOLITO VINCENT P
EVP & Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2016-01-19$19.96/sh+20,000$399,20090,985 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2016-01-1920,00061,000 total
    Exercise: $19.96Exp: 2024-03-06Common Stock (20,000 underlying)
  • Sale

    Common Stock

    2016-01-19$96.00/sh5,300$508,79771,185 total
  • Sale

    Common Stock

    2016-01-19$93.92/sh1,200$112,70489,785 total
  • Sale

    Common Stock

    2016-01-19$95.29/sh13,300$1,267,31376,485 total
  • Sale

    Common Stock

    2016-01-19$96.95/sh200$19,39070,985 total
Footnotes (6)
  • [F1]This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.68 to $94.575, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.72 to $95.63, inclusive.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.78 to $96.74, inclusive.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.84 to $97.06, inclusive.
  • [F6]The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting each month thereafter. The Vesting Commencement Date was February 28, 2014.

Issuer

Anacor Pharmaceuticals, Inc.

CIK 0001411158

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001411158

Filing Metadata

Form type
4
Filed
Jan 20, 7:00 PM ET
Accepted
Jan 21, 9:00 PM ET
Size
14.9 KB